jili1111
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 8, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favor of Polivy in combination with R-CHP compared to Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, M.D., Ph.D., chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% versus 61.7%). At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% versus 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the U.S., countries throughout the EU, the U.K., Japan, Canada and China. Genentech continues to work with health authorities around the world to bring this treatment regimen to even more patients. Genentech aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Genentech is exploring Polivy in combination with other molecules, including its bispecific antibodies. Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the Phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi ® (glofitamab-gxbm) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX Study POLARIX [ NCT03274492 ] is an international Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy ® (polatuzumab vedotin-piiq) plus Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) versus Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomized 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of Rituxan. The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Side effects seen most often The most common side effects during treatment were Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit https://www.Polivy.com for additional Important Safety Information. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers. Lunsumio U.S. Indication Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if Lunsumio is safe and effective in children. The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Lunsumio? Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: Due to the risk of CRS, you will receive Lunsumio on a “step-up dosing schedule.” Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects. What are the possible side effects of Lunsumio? Lunsumio may cause serious side effects, including: Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects. The most common side effects of Lunsumio include: tiredness, rash, fever, and headache. The most common severe abnormal blood test results with Lunsumio include: decreased phosphate, increased glucose, and increased uric acid levels. Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Lunsumio? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full Prescribing Information and Medication Guide or visit https://www.Lunsumio.com . About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio ® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: Due to the risk of CRS, you will receive Columvi on a “step-up dosing schedule”. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . Dr. Salles has financial interests related to Roche and Genentech. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208818007/en/ CONTACT: Media Contact: Kristen Ingram, (650) 467-6800Advocacy Contact: Catherine Creme Henry, (202) 258-8228Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, 011 41 61 687 5284 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Genentech Copyright Business Wire 2024. PUB: 12/08/2024 12:30 PM/DISC: 12/08/2024 12:30 PM http://www.businesswire.com/news/home/20241208818007/en
Advertisement 2 This advertisement has not loaded yet.
Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably deserving Alabama team on the sideline in favor of an SMU squad with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and banged-up Georgia like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, whose undefeated Ducks are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. Coming up short The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” First round byes Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. Automatic byes and bids made the bracket strange The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. First round matchups No. 12 Clemson at No. 5 Texas, Dec. 21: Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? No. 11 SMU at No. 6 Penn State, Dec. 21: The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. No. 10 Indiana at No. 7 Notre Dame, Dec. 20: Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner gets ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? No. 9 Tennessee at No. 8 Ohio State, Dec. 21: The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later.
Wall Street Brunch: Last Leg Of Inflation Battle Is The Longest
South Korea’s markets vulnerable after weekend of political stalemateRADFORD, Va. (AP) — Jarvis Moss scored 15 points and Jonas Sirtautas had a go-ahead three-point play in overtime to help Radford hold off Bucknell 74-70 on Sunday night. Sirtautas gave the Highlanders the lead for good with 2:38 left in the extra period. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week
Iowa moves on without injured quarterback Brendan Sullivan when the Hawkeyes visit Maryland for a Big Ten Conference contest on Saturday afternoon. Former starter Cade McNamara is not ready to return from a concussion, so Iowa (6-4, 4-3) turns to former walk-on and fourth-stringer Jackson Stratton to lead the offense in College Park, Md. "Confident that he'll do a great job," Iowa coach Kirk Ferentz said of Stratton on his weekly radio show. "He stepped in, did a really nice job in our last ballgame. And he's got a good ability to throw the football, and he's learning every day. ... We'll go with him and see what we can do." Iowa had been on an upswing with Sullivan, who had sparked the Hawkeyes to convincing wins over Northwestern and Wisconsin before suffering an ankle injury in a 20-17 loss at UCLA on Nov. 8. Stratton came on in relief against the Bruins and completed 3 of 6 passes for 28 yards. Another storyline for Saturday is that Ferentz will be opposing his son, Brian Ferentz, an assistant at Maryland. Brian Ferentz was Iowa's offensive coordinator from 2017-23. "We've all got business to take care of on Saturday," Kirk Ferentz said. "I think his experience has been good and everything I know about it. As a parent, I'm glad he's with good people." Maryland (4-6, 1-6) needs a win to keep its hopes alive for a fourth straight bowl appearance under Mike Locksley. The Terrapins have dropped five of their last six games, all by at least 14 points, including a 31-17 loss at home to Rutgers last weekend. "It's been a challenging last few weeks to say the least," Locksley said. The challenge this week will be to stop Iowa running back Kaleb Johnson, who leads the Big Ten in rushing yards (1,328) and touchdowns (20), averaging 7.1 yards per carry. "With running backs, it's not always about speed. It's about power, vision and the ability to make something out of nothing," Locksley said. "This guy is a load and runs behind his pads." Maryland answers with quarterback Billy Edwards Jr., who leads the Big Ten in passing yards per game (285.5) and completions (268). His top target is Tai Felton, who leads the conference in catches (86) and receiving yards (1,040). --Field Level MediaAnge Postecoglou knows the next month will be “significant” for Tottenham, but is confident they will improve and not be mid-table at Christmas. Spurs travel to Premier League champions Manchester City on Saturday reeling from a disappointing home loss to Ipswich before the international break. The club’s problems have multiplied during the past fortnight with midfielder Rodrigo Bentancur handed a seven-match domestic ban on Monday and Cristian Romero (toe) joining a lengthy list of absentees. However, Postecoglou remains bullish about Tottenham’s progress and acutely aware of the scrutiny set to come his way if they stay 10th. “Christmas is a joyous occasion, irrespective, and I think it should be celebrated. If we’re still 10th then people won’t be happy, I won’t be happy, but we might not be 10th,” Postecoglou pointed out before nine games in 30 days. “Certainly for us I think it’s a significant period because you look at those games and we’ve got the league where we’ve got to improve our position and a couple of important European fixtures that can set us up for the back half of the year, also a Carabao Cup quarter-final. “At the end of that period we could be in a decent position for a strong second half of the year, so for us it is an important period. “You know there’s no more international breaks, so the full focus is here. You can build some momentum through that, or if things don’t go well you could get yourself into a bit of a grind. “Of course if we had beaten Ipswich, we’d be third and I reckon this press conference would be much different wouldn’t it? “I’m not going to let my life be dictated by one result, I’m sorry. I take a wider perspective on these things because I know how fickle it can be, but we need to address our position for sure. “And if we’re 10th at Christmas, yeah it won’t be great. There’d be a lot of scrutiny and probably a lot of scrutiny around me, which is fair enough, but that’s not where I plan for us to be.” Tottenham’s immediate efforts to move up the table will require them ending City’s two-year unbeaten home run in the Premier League. The champions have lost their last four matches in all competitions, but have some key personnel back for Saturday’s clash and will aim to toast Pep Guardiola’s new contract with a victory. Postecoglou was pleased to see Guardiola commit to a further two seasons in England, adding: “I love the fact that there’s a massive target out there that can seem insurmountable. “I look at it the other way. I go, ‘imagine if you knock him off, that’d be something’. “I’m at the stage of my life where I’d rather have the chance of knocking him off than missing that opportunity. “When greatness is around, you want to be around it. And hopefully it challenges you to be like that as well.” Saturday’s fixture will be Postecoglou’s 50th league game in charge of Spurs and he knows what is required to bring up three figures. “I took over a club that finished eighth,” Postecoglou said. “No European football, significant player turnover, change of playing style. Where did I think we’d be after 50 games? God knows. “It could have been a whole lot worse, but when you look at it in the current prism of we’re 10th, you’re going ‘it doesn’t look good’ and I understand that and we have to improve that. “But over the 50 games, I think there’s enough there that shows we are progressing as a team and we are developing into the team we want. “The key is the next 50 games, if they can be in totality better than the first 50? First, that means I’m here but second, I think we’ll be in a good space.”
Super Micro Computer, lululemon And Roku Are Among Top 11 Large Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?WASHINGTON — President-elect Donald Trump picked Scott Bessent to serve as Treasury secretary Friday, tapping a billionaire hedge fund manager to lead an economic agenda that is expected to be built around raising tariffs and cutting taxes. Bessent, the founder of the investment firm Key Square Capital Management, has emerged as a central economic adviser to Trump over the past year. He has called for rolling back government subsidies, deregulating the economy and raising domestic energy production. Unlike many on Wall Street, Bessent, 62, has also defended the use of tariffs, which are Trump’s favorite economic tool. “Scott is widely respected as one of the World’s foremost International Investors and Geopolitical and Economic Strategists,” Trump said in a statement posted on social media. “Scott’s story is that of the American Dream.” “Together, we will Make America Rich Again, Prosperous Again, Affordable Again, and most importantly, Great Again,” Trump said. Although Bessent’s policy ideas are in lockstep with conservative economic principles, one aspect of his background could draw questions from Republicans. He rose to prominence in the finance world as a protégé of George Soros, a billionaire Democratic donor and longtime villain of the right wing, and served for years as his top money manager. Related Story: The selection came after intensive deliberation by Trump and his advisers, who debated for weeks about who should win the most prominent economic job in his administration. Bessent and Howard Lutnick, the CEO of Cantor Fitzgerald, tussled over the job before Lutnick was picked to be commerce secretary this week. Trump also considered tapping Kevin Warsh, a former Federal Reserve Board governor, and Marc Rowan, the CEO of Apollo Global Management, for the role. If confirmed by the Senate, Bessent would take over a department with vast responsibilities that is at the core of the federal government. The Treasury Department issues debt to fund the government’s operations and pay its bills, including paying Social Security and veterans benefits. But the most visible parts of Bessent’s job will be shepherding the administration’s tax plans through Congress, leading economic negotiations with China and overseeing the nation’s sanctions program. — This article originally appeared in . By Alan Rappeport and Maggie Haberman c.2024 The New York Times Company
Conor McGregor embarked on a social media rampage as he called rape accuser Nikita Hand a "vicious liar" after a civil jury found that the MMA fighter sexually assaulted his accuser in a Dublin hotel in 2018. The 36-year-old was found liable by a jury in the High Court in the Irish capital , as $259,002.55 was awarded to the complainant in the civil trial. The allegations were first made by Ms Hand in 2021, with the verdict eventually delivered after six hours and ten minutes of deliberation from the jury on Nov. 22. This followed an eight-day trial, during which the former UFC champion admitted he had consensual sex with Ms Hand, as well as taking cocaine with her. McGregor having since vowed to appeal against the decision , while it was determined by the jury that a second defendant, James Lawrence, was cleared of any wrongdoing after being accused of assault. Every word Conor McGregor's rape accuser said outside court after winning case Conor McGregor loses rape case as UFC star learns jury verdict McGregor has now taken to social media to give his view on the findings of the civil trial, as posted the following message on Twitter/X: "Justice was served for James Lawrence, yes! Deplorable what they done. Nikita Hand, vicious liar! APPEAL! "Two men falsely accused. One vindicated, the other soon to be! Congrats James Lawrence on absolute exoneration! Twice this heinous accusation was put to you and twice it was shown as FALSE! LIES! "It is absolutely disgraceful what they put you through here. Disgraceful! I look forward to seeing you further vindicate yourself and lambast those responsible in court! We know what happened that night! Everyone present knows, yet it was ignored. Every single statement of persons present on the night was ignored. And they all disputed Nikita’s LIES! "However James they did believe you but just in certain parts for some strange reason. And they apparently did not believe Danielle Kealy at all. Laughable! Also with the damages (60k and 188k, interesting choice of figures it seems they didn’t believe Nikita much either. How could they, her original story was she was gang raped by security and chased from the hotel on foot. "Absolute nonsense. How these lies were accepted, I will never know. A court of feeling and opinion, brainwashed in to people via the mainstream media. Not of fact! The reporting in court a laughing stock to everyone present. As clear as day bias. This is not a court of hard evidence and truth." DON'T MISS: UFC president Dana White makes Donald Trump U-turn after election victory Jon Jones handed suspension after brutal ending to UFC 309 fight Dave Portnoy takes aim at Zach Bryan after UFC star gets caught up in feud He added: "It is a kangaroo court of opinions and feelings. We are not done yet. Not by a long shot. No chance. On we fight! Justice and truth will prevail! Appeal! Appeal! Appeal! As well as other. Congrats James! Onwards and upwards!" Speaking after the conclusion of the civil trial, Ms Hand issued a statement as she expressed gratitude for the support she has received during proceedings. She said: "I would like to start off by saying I’m overwhelmed and touched by the support I have received from everybody.” “I want to thank all the women and men out there who have supported me throughout this trial. For every person who reached out to me – a card, a letter, an email, everything – it hasn’t gone unnoticed. Thank you, I really appreciate it so much. Ms Hand added: "I know this has impacted not only my life, my daughter’s, my family and friends tremendously. It’s something that I’ll never forget for the rest of my life. Now that justice has been served, I can now try and move on and look forward to the future with my family and friends and daughter."'Trust and reserve judgement' on rebrand, says JaguarIn a conglomerate run by cousins, one ‘primo’ speaks power
Dilok Klaisataporn LGLV strategy SPDR® SSGA US Large Cap Low Volatility Index ETF ( NYSEARCA: LGLV ) was listed on 02/20/2013 and tracks the SSGA US Large Cap Low Volatility Index. It has a portfolio of 163 stocks, a 30-day SEC yield Quantitative Risk & Value (QRV) provides you with risk indicators and data-driven, time-tested strategies. Get started with a two-week free trial now. Fred Piard, PhD. is a quantitative analyst and IT professional with over 30 years of experience working in technology. He is the author of three books and has been investing in data-driven systematic strategies since 2010. Quantitative Risk & Value Learn more Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
